Jefferies Healthcare Conference

Size: px
Start display at page:

Download "Jefferies Healthcare Conference"

Transcription

1 Jefferies Healthcare Conference Jean-Marc BOTHY - CSO June 8, IBA SA

2 Disclaimer This presentation may contain forward-looking statements concerning industry outlook, including growth drivers; the company s future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology and any statements using the terms could, believe, outlook, or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company s actual results to differ materially from those anticipated. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise. 2

3 IBA at a glance A world leading innovator in cancer diagnostics and treatment Number one provider of proton therapy solutions Global leader in dosimetry and particle accelerators 1,500 employees worldwide and growing 329M Most advanced PT offering Single and multi room systems equipped with cutting edge technology *Proteus ONE and Proteus PLUS are brand names of Proteus 235 3

4 IBA a global leader in proton therapy Share of installed base - rooms Total accumulated: 250 rooms IBA market share is 56% in US, 54% in APAC ex. Japan and 56% in EUR & ROW Including commercial PT rooms at end

5 IBA Group 2016 key figures 5

6 Proton therapy market drivers today s capacity gap Source : IBA internal modeling based on Model Based Approach developed in The Netherlands ( 6

7 Proton therapy capacity gap Estimation of RT and PT rooms needed by Radiotherapy rooms needed by 2035 estimated by Lancet Oncology Proton therapy rooms needed by 2035 extrapolated worldwide from the Horizon Scanning : Proton Therapy in the Netherlands apy200917e_0.pdf 7

8 IBA strategy 8

9 Why proton therapy? (The dose deposition) The therapeutic index Tumor control probability (TCP) Normal tissue complication probability (NTCP) Define the maximal dose deliverable as a function of acceptable tolerance Courtesy of El Naqa et al 2006a Int. J. Radiat. Oncol. Biol. Phys Courtesy of Prof Lagendijk 11

10 Proton therapy vs conventional radiotherapy Highest dose is near the point of beam entry. Highest dose is at the depth of the tumor target. Tumor dose is less than the entry dose. Dose is also delivered beyond the tumor target. Zero or almost no dose beyond Minimal radiation exposure of healthy organs Potential to reduce the risk of secondary cancers Potential to improve the quality of life for patients during and after treatment Possibility of retreatment 12

11 Updated PT global market dynamics Number of patients treated with PT rose 21% between 2012 and 2015 to (cumulated) Number of patients treated with PT in 2015: This still represents less than 1% of the ~ cancer patients treated every year with radiotherapy Patients treated Total rooms sold Room in operations Source: MEDraysintell 2016, IBA model, PTCog 2016, and others 11

12 Increasing relevance of proton therapy 108 trials open and recruiting Publications statistics per year End December 2016 Number of publications up to end of 2016 Data from

13 Rate of sales increasing 55% vs previous years PT market number of rooms sold per year Wider acceptance of PT Competitive dynamics Lower entry barriers to PT Technology evolving More centres opening Average p.a. 13

14 IBA s unique proton therapy solutions 360 m² Proteus ONE Proton therapy made easy Proteus PLUS Excellence in proton therapy 1800 m² Compact single-room IMPT solution Proteus ONE and Proteus PLUS are the brand names of the Proteus 235 Tailor-made IMPT solution 16

15 Size matters ProteusONE Other 360 gantry one room system Footprint Volume

16 Rational for compact one room system Budget for one room system Up to 35% more affordable 3 months longer to instal 3 times larger building ProteusONE Other 360 gantry one room system Proton therapy system OIS/TPS Building development costs financial cost Start-up expenses System 3 times heavier 16

17 No compromises PROVEN PENCIL BEAM SCANNING For highly conformal IMPT INSTANT 3D & CONE- BEAM CT* For Image-Guided PT PATIENT AND STAFF FRIENDLY Open environment Protect, Enhance and Save Lives 17

18 Proton therapy centers equipped by IBA (end 2016) Systems 21 Systems Treating Patients & 17 Systems in Construction & 8 Systems in Installation Total: 46 Systems Rooms 67 Rooms Treating Patients & 24 Rooms in Construction & 20 Rooms in Installation Total: 111 Rooms 2016: 8 systems sold (5 Proteus One) in US, UK, China, India, UAE and Belgium 2017: 2 Proteus One sold (Spain and Egypt) and selection for another Proteus One in Belgium. Proteus ONE Proteus PLUS 18

19 Our strategy is to create a virtuous circle in PT Enhance market penetration Develop regionalization Leverage partnership Strengthen market leadership Invest in clinical affairs initiatives Focus on product roadmap Accelerate PT adoption PARTNERSHIPS Build clinical & cost advantage Increase clinical relevance Reduce cost of modality 19

20 Expansion strategy new factory Assembly, integration and test of accelerators for Proteus ONE CAPEX: EUR 16 million investment program over 2 years Digital factory Green and sustainable Lean total combined capacity of 20 to 30 accelerators per year (from 8 to 10 today) Opening in Q

21 Image-guided proton therapy courtesy of Roberts Proton Therapy Center CBCT Penn Medicine, USA CT-on-rails, Trento, Italy 21

22 Excellence in proton therapy: integration TPS/OIS: open vendor strategy (freedom to choose according to your need) Treatment planning Oncology information system Proton treatment delivery system Xio (Elekta) : 12 centers Eclipse (Varian) : 7 centers RayStation (Raysearch) : 17 centers Mosaiq (Elekta) : 20 centers Aria (Varian) : 3 centers RayCare (Raysearch): In development IBA Pinnacle*(Philips) : 4 sites 22 30

23 2017 Q1 update Group revenues of EUR 73,2 million, up 13,5% compared to first quarter 2016 Proton Therapy and Other accelerators backlog amounts to EUR 316 million Proton Therapy revenues continue to grow with 8 projects now under installation simultaneously Other Accelerators show a drop from last year. Last year was boosted by the installation of two large high energy cyclotrons Dosimetry returns to growth up 19% to EUR 14.5 million Q (EUR 000) Q (EUR 000) Variance (EUR 000) Variance % Proton therapy ,8% Other Accelerators ,6% Dosimetry ,2% Total Net Sales ,4% 23

24 Guidance IBA expects to achieve revenue growth between 15% to 20% in 2017 and double digit thereafter The Company expects its operating margin to be 10% to 12% in 2017, increasing to around 13% by 2018 and stabilizing at around 15% by % dividend pay-out ratio target maintained for 2017 This guidance is not only based upon the continued expected growth of the proton therapy market but also the balance between the economies of scale that we can achieve at a higher production rate. In addition, the growing importance of service revenue versus the increased demand driven by the equipment price tag reduction in the proton therapy market and our continued investment in R&D and software capabilities are anticipated to be contributing factors. 24

25 Thank you Protect, Enhance and Save Lives 25

The Best in Proton Therapy + Today and Tomorrow + IBA. Corporate Presentation. February 2017

The Best in Proton Therapy + Today and Tomorrow + IBA. Corporate Presentation. February 2017 The Best in Proton Therapy + Today and Tomorrow + IBA Corporate Presentation February 2017 Disclaimer This presentation may contain forward-looking statements concerning industry outlook, including growth

More information

Press release Regulated information

Press release Regulated information IBA TRADING UPDATE - THIRD QUARTER 2013 Pick up in revenues over H1 2013 due to good order book conversion Company on track to be selected for eight new proton therapy (PT) rooms in 2013 REBIT margin for

More information

Annual Shareholders Meeting

Annual Shareholders Meeting Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking

More information

PROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION

PROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION Proton Therapy Edition 2016 PROTON THERAPY WORLD MARKET REPORT & DIRECTORY EDITION 2016 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/7 www.medraysintell.com Proton Therapy Edition

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

January 2018 Dow Wilson President and Chief Executive Officer

January 2018 Dow Wilson President and Chief Executive Officer J.P. Morgan 2018 Healthcare Conference January 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing.

More information

Proton Therapy Market Outlook - Global Analysis

Proton Therapy Market Outlook - Global Analysis Proton Therapy Market Outlook - Global Analysis Proton Therapy Market Outlook - Global Analysis BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen

More information

JP MORGAN HEALTHCARE CONFERENCE DOW R. WILSON President and Chief Executive Officer 1 FOR INVESTOR USE ONLY

JP MORGAN HEALTHCARE CONFERENCE DOW R. WILSON President and Chief Executive Officer 1 FOR INVESTOR USE ONLY JP MORGAN HEALTHCARE CONFERENCE - 2017 DOW R. WILSON President and Chief Executive Officer 1 FOR INVESTOR USE ONLY THIS PRESENTATION IS INTENDED EXCLUSIVELY FOR INVESTORS. IT IS NOT INTENDED FOR USE IN

More information

Elekta Synergy Digital accelerator for advanced IGRT

Elekta Synergy Digital accelerator for advanced IGRT Elekta Synergy Digital accelerator for advanced IGRT Setting the standard for confident care The Field of Radiation Therapy is Constantly Changing Being able to take full advantage of the latest clinical

More information

FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE. Geoffrey S. Ibbott, Ph.D. June 20, 2017

FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE. Geoffrey S. Ibbott, Ph.D. June 20, 2017 FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE Geoffrey S. Ibbott, Ph.D. June 20, 2017 1 DISCLOSURES My institution holds Strategic Partnership Research Agreements with Varian, Elekta, and Philips

More information

THE BEST IN PROTON THERAPY TODAY AND TOMORROW

THE BEST IN PROTON THERAPY TODAY AND TOMORROW THE BEST IN PROTON THERAPY TODAY AND TOMORROW The figures speak for themselves As the leading provider of Proton Therapy, IBA is committed to making this advanced treatment available to cancer patients

More information

Elekta Innovation and Growth. ESTRO 2012 Capital Markets Presentation

Elekta Innovation and Growth. ESTRO 2012 Capital Markets Presentation Elekta Innovation and Growth ESTRO 2012 Capital Markets Presentation 15.00 Introduction Partner in cancer care Growth Tomas Puusepp President and CEO 15.30 Patient-focused development Cancer care solutions

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

Global Radiation Therapy Market Report

Global Radiation Therapy Market Report Global Radiation Therapy Market Report ----------------------------------------- 2013 Executive Summary Radiotherapy is used to kill cancerous cells and is commonly used either alone or in combination

More information

For personal use only

For personal use only Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group

More information

INVESTOR MEETING ASTRO 2013

INVESTOR MEETING ASTRO 2013 INVESTOR MEETING ASTRO 2013 Webcast will begin 7:15 a.m. EDT SEPTEMBER 24, 2013 2013 VARIAN MEDICAL SYSTEMS. ALL RIGHTS RESERVED. Forward-Looking Statements Except for historical information, this news

More information

Imaging Systems. Gene Saragnese EVP and GM Imaging Systems

Imaging Systems. Gene Saragnese EVP and GM Imaging Systems Imaging Systems Gene Saragnese EVP and GM Imaging Systems 1 Imaging Systems Strategy Drive Customer & Patient Experience Quality, reliability and service delivery Ease of use, speed, comfort, dose Deliver

More information

PROTON THERAPY. MEDraysintell WORLD MARKET REPORT & DIRECTORY EDITION

PROTON THERAPY. MEDraysintell WORLD MARKET REPORT & DIRECTORY EDITION MEDraysintell PROTON THERAPY WORLD MARKET REPORT & DIRECTORY EDITION 2018 A report written by Paul-Emmanuel Goethals & Richard Zimmermann 2018 www.medraysintell.com Proton Therapy remains a niche market,

More information

Elekta Infinity Digital accelerator for advanced treatments

Elekta Infinity Digital accelerator for advanced treatments Elekta Infinity Digital accelerator for advanced treatments Redefining treatment precision, speed and control Confidence to increase conformance and speed without compromising target coverage Set yourself

More information

Elekta: Emerging markets

Elekta: Emerging markets Gynecologic Cancer InterGroup Cervix Cancer Research Network Elekta: Emerging markets Cervix Cancer Education Symposium, January 2016, Bangkok, Thailand 144,000 deaths were related to cervical cancer in

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Elekta R&D Update 22 January 2015, Utrecht

Elekta R&D Update 22 January 2015, Utrecht 1 Elekta R&D Update 22 January 2015, Utrecht Elekta R&D Update - 22 January 2015, Utrecht 11.00 R&D Update Niklas Savander President and CEO 11.15 Atlantic Positioning Dee Mathieson, SVP Oncology Business

More information

CYCLOTRONS WORLD MARKET REPORT & DIRECTORY EDITION TOC and Summary USED IN NUCLEAR MEDICINE MARKET DATA, COMPANIES PROFILES.

CYCLOTRONS WORLD MARKET REPORT & DIRECTORY EDITION TOC and Summary USED IN NUCLEAR MEDICINE MARKET DATA, COMPANIES PROFILES. CYCLOTRONS USED IN NUCLEAR MEDICINE WORLD MARKET REPORT & DIRECTORY MARKET DATA, COMPANIES PROFILES TOC and Summary EDITION 2015 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/5

More information

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset

More information

GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008

GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord A/S GN GN Store Store Nord Nord Listed Listed company

More information

Closing of Nucletron acquisition Building a stronger position in the cancer care market. September 15, 2011

Closing of Nucletron acquisition Building a stronger position in the cancer care market. September 15, 2011 Closing of Nucletron acquisition Building a stronger position in the cancer care market September 15, 2011 Important step in Elekta s growth strategy Nucletron is the world leader in Brachytherapy and

More information

INSERT COMPANY LOGO HERE

INSERT COMPANY LOGO HERE 2013 2014 INSERT COMPANY LOGO HERE 2014 North American 2013 North Positron American Emission SSL Tomography Certificate (PET) Imaging Technology Product Innovation Leadership Leadership Award Award Industry

More information

Integration of PT in an existing radiation oncology center

Integration of PT in an existing radiation oncology center Integration of PT in an existing radiation oncology center Tom Depuydt, PhD Head of medical Physics, Radiation Oncology UZ Leuven-KU Leuven and ParTICLe proton therapy project tom.depuydt@uzleuven.be 1

More information

Modern Hadron Therapy Gantry Developments. 16th Jan 2014

Modern Hadron Therapy Gantry Developments. 16th Jan 2014 Modern Hadron Therapy Gantry Developments 16th Jan 2014 Protect, Enhance, and Save Lives - 2 - IBA ProteusONE THE TREND: MORE COMPACT, CHEAPER Access to PT is key ProteusPLUS ProteusONE 18000 ft² / 1672

More information

Plans for the Precision Cancer Medicine Institute University of Oxford

Plans for the Precision Cancer Medicine Institute University of Oxford Plans for the Precision Cancer Medicine Institute University of Oxford STFC & Particle Accelerators and Beams group workshop on particle accelerators for medicine 17 th February 2015 Claire Timlin The

More information

IBA Dosimetry Company Presentation. Patient Safety & Quality Control

IBA Dosimetry Company Presentation. Patient Safety & Quality Control IBA Dosimetry Company Presentation Patient Safety & Quality Control IBA Mission Protect, enhance and save lives Protect, Enhance, and Save Lives - 2 - The History of IBA Dosimetry A story of innovation

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,

More information

Universal Biosensors, Inc.

Universal Biosensors, Inc. Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended

More information

Focusing our energy on saving lives

Focusing our energy on saving lives October 2017 The Outlook for Oncology: The Shrinking, Affordable Proton Therapy Center Focusing our energy on saving lives Jonathan Farr, DSc Senior Vice President Medical Physics Forward Looking Statement

More information

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

An exciting combination in a high growth, high margin Nutrition category. Name of chairman An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views

More information

Nestlé Investor Seminar 2008

Nestlé Investor Seminar 2008 Nestlé Investor Seminar 2008 Nestlé Nutrition update on Acquisitions Richard Laube CEO Nestlé Nutrition 1 Disclaimer This presentation contains forward looking statements which reflect Management s current

More information

Radiation Oncology. The conf ident path to treatment Philips Radiation Oncology Solutions

Radiation Oncology. The conf ident path to treatment Philips Radiation Oncology Solutions Radiation Oncology The conf ident path to treatment Philips Radiation Oncology Solutions The confident path to treatment Philips Radiation Oncology Solutions Imaging Image registration Contouring Treatment

More information

SUMITOMO Particle Therapy Technologies

SUMITOMO Particle Therapy Technologies 55 th AAPM annual meeting Particle Beam Therapy Symposium SUMITOMO Particle Therapy Technologies August 3, 2013 Yukio Kumata Experience accelerators for science Current Status proton and carbon Future

More information

1ª Jornada de Análisis de Riesgos en RT. 10 de Dic 2014 José Luis Roldán

1ª Jornada de Análisis de Riesgos en RT. 10 de Dic 2014 José Luis Roldán Risk in Dosimetry. Industry Stand point 1ª Jornada de Análisis de Riesgos en RT. 10 de Dic 2014 José Luis Roldán Agenda IBA. IBA Dosimetry Risks in Dosimetry Product development Product manufacturing Product

More information

A GLOBAL LEADER IN PERSONALIZED NUTRITION

A GLOBAL LEADER IN PERSONALIZED NUTRITION A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking

More information

Clinical Education A comprehensive and specific training program. carry out effective treatments from day one

Clinical Education A comprehensive and specific training program. carry out effective treatments from day one Proton Therapy Clinical Education A comprehensive and specific training program carry out effective treatments from day one Forewarned is forearmed Although over 100,000 patients have been treated in proton

More information

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Media release Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Growth driven by implant volumes, lifted by Bone Level implant range and Roxolid Third quarter (+3%

More information

United States Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022

United States Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 United States Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 United States Proton Therapy Market (Actual & Potential), Patients Treated,

More information

Efficient Dosimetry for Proton Therapy

Efficient Dosimetry for Proton Therapy Efficient Dosimetry for Proton Therapy Why IBA Dosimetry? IBA Dosimetry offers the full product range tailored to fit any Proton Therapy QA needs. PT treatment safety, as well as most efficient dosimetry

More information

Continuing the momentum to deliver improved performance. Robert Cascella Chief Business Leader Diagnosis & Treatment

Continuing the momentum to deliver improved performance. Robert Cascella Chief Business Leader Diagnosis & Treatment Continuing the momentum to deliver improved performance Robert Cascella Chief Business Leader Diagnosis & Treatment Key takeaways Diagnosis & Treatment strategy is aligned with the Quadruple Aim Gaining

More information

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014 Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains

More information

SCANNER & SERVICES OVERVIEW

SCANNER & SERVICES OVERVIEW SCANNER & SERVICES OVERVIEW Tim Mack VP BUSINESS DEVELOPMENT & GM ITERO 1 2014 Align Technology, Inc. 1 FORWARD LOOKING STATEMENT During this presentation and corresponding commentary we may make forwardlooking

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

iba-worldwide.com REACHING MORE PATIENTS

iba-worldwide.com REACHING MORE PATIENTS iba-worldwide.com REACHING MORE PATIENTS IBA s Mission TO DEVELOP CUTTING-EDGE TECHNOLOGY IN THE FIGHT AGAINST CANCER IBA is the world leader in cutting-edge technology as applied to radiotherapy treatment

More information

CEO Operational Report. Annual General Meeting 23 October 2013

CEO Operational Report. Annual General Meeting 23 October 2013 CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting

More information

Image Guided Proton Therapy and Treatment Adaptation

Image Guided Proton Therapy and Treatment Adaptation Image Guided Proton Therapy and Treatment Adaptation www.hollandptc.nl d.r.schaart@tudelft.nl Cancer in The Netherlands About 1 in 3 people get cancer in some stage of their life 86.800 new cancer patients

More information

DIGITAL DIABETES CARE MARKET READY TO TAKE OFF

DIGITAL DIABETES CARE MARKET READY TO TAKE OFF DIGITAL DIABETES CARE MARKET 2018-2022 READY TO TAKE OFF www.research2guidance.com A market study about diabetes apps, connected devices, and services 3 rd edition, 3 rd September 2018 Research2Guidance

More information

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

Overview of Advanced Techniques in Radiation Therapy

Overview of Advanced Techniques in Radiation Therapy Overview of Advanced Techniques in Radiation Therapy Jacob (Jake) Van Dyk Manager, Physics & Engineering, LRCP Professor, UWO University of Western Ontario Acknowledgements Glenn Bauman Jerry Battista

More information

Elekta - a partner and world-leading supplier

Elekta - a partner and world-leading supplier Experience Elekta Elekta - a partner and world-leading supplier of clinical solutions for image guided radiation therapy, stereotactic radiotherapy, radiosurgery and brachytherapy, as well as advanced

More information

Varian and BrainLAB this historically strong relationship has evolved and is set to unlock infinite possibilities Varian Medical Systems, the world s leading manufacturer of radiotherapy and radiosurgery

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

AccuBoost non invasive, real-time, image guided breast boosting

AccuBoost non invasive, real-time, image guided breast boosting AccuBoost non invasive, real-time, image guided breast boosting A new treatment option for the boost dose as part of the Whole Breast Irradiation treatment after breast cancer AccuBoost is a new system

More information

iviewdose Confidence and assurance in dose delivery

iviewdose Confidence and assurance in dose delivery iviewdose Confidence and assurance in dose delivery As radiotherapy techniques advance and treatment plans become more complex, involving escalated doses and increasingly conformal deliveries, the need

More information

Essential Oil & Aromatherapy Market Research Report- Forecast to 2023

Essential Oil & Aromatherapy Market Research Report- Forecast to 2023 Report Information More information from: https://www.marketresearchfuture.com/reports/3319 Essential Oil & Aromatherapy Market Research Report- Forecast to 2023 Report / Search Code: MRFR/F-B & N/2386-HCRR

More information

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,

More information

Myriad Genetics Corporate Presentation 06/13/2018

Myriad Genetics Corporate Presentation 06/13/2018 Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today

More information

Protura Robotic Patient Positioning System. for efficiency + performance

Protura Robotic Patient Positioning System. for efficiency + performance Protura Robotic Patient Positioning System for efficiency + performance Protura Robotic Patient Positioning System The Protura Robotic Patient Positioning System is the ultimate in robotic patient motion

More information

Hong Kong Sanatorium & Hospital Introduces First-in-Asia TomoHD System

Hong Kong Sanatorium & Hospital Introduces First-in-Asia TomoHD System For Immediate Release Hong Kong Sanatorium & Hospital Introduces First-in-Asia TomoHD System (8 March 2011, Hong Kong) Hong Kong Sanatorium & Hospital (HKSH) announces today the introduction of the first-in-asia

More information

Putting ALK on the right growth trajectory

Putting ALK on the right growth trajectory Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large

More information

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission

More information

Workshop on Hadron Beam Therapy of Cancer Erice, Sicily April 24-May

Workshop on Hadron Beam Therapy of Cancer Erice, Sicily April 24-May IONTRIS Synchrotron based PT Solutions from Siemens AG Workshop on Hadron Beam Therapy of Cancer Erice, Sicily April 24-May 1 2009 Matthias Herforth VP Business Development and Communications Siemens AG

More information

Michael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation

Michael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,

More information

The Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD. The Promise of Protons

The Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD. The Promise of Protons The Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD The Promise of Protons The Promise of Protons Cancer and radiation therapy The promise of protons UFHPTI: missions and operation

More information

Corporate Presentation Fourth Quarter 2017

Corporate Presentation Fourth Quarter 2017 Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

Economic Implications of Advancements in Radiation Technology. Dramatic Growth of RT Capacity in the US

Economic Implications of Advancements in Radiation Technology. Dramatic Growth of RT Capacity in the US Economic Implications of Advancements in Radiation Technology Sponsored by: OTN Anthony M. Berson, M.D. Radiation Oncology, St. Vincent s Comprehensive Cancer Center Richard Emery Vice President, Aptium

More information

Poland Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022

Poland Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 Poland Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 Poland Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton

More information

Robotic Spine Surgery [TASE]: MZOR

Robotic Spine Surgery [TASE]: MZOR Robotic Spine Surgery [TASE]: MZOR Nov. 2012 Forward Looking Statements Any forecast and/or forecasting statement, included in this presentation, is based on the Management's assessment at its discretion.

More information

Expanding the boundaries of nutrition Luis Cantarell

Expanding the boundaries of nutrition Luis Cantarell Expanding the boundaries of nutrition Luis Cantarell Nestlé Investor Seminar 30 September 2013 Disclaimer This presentation contains forward looking statements which reflect Management s current views

More information

PROGRESS IN HADRONTHERAPY

PROGRESS IN HADRONTHERAPY PROGRESS IN HADRONTHERAPY Saverio Braccini TERA Foundation for Oncological Hadrontherapy IPRD06 - Siena - 01.10.06 - SB 1 Outline Introduction Radiation therapy with X rays and hadrontherapy Hadrontherapy

More information

Financial Presentation

Financial Presentation Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with

More information

4 th Quarter 2017 Earnings Review & Investor Update

4 th Quarter 2017 Earnings Review & Investor Update 4 th Quarter 2017 Earnings Review & Investor Update February 5, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking

More information

Cepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012

Cepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012 Cepheid The MDx Growth Leader William Blair Growth Stock Conference June 12, 2012 Forward Looking Statement During the course of this presentation, we may make projections or other forward looking statements

More information

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with

More information

Important information

Important information Important information This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar

More information

Varian Acuity BrachyTherapy Suite One Room Integrated Image-Guided Brachytherapy

Varian Acuity BrachyTherapy Suite One Room Integrated Image-Guided Brachytherapy Varian Acuity BrachyTherapy Suite One Room Integrated Image-Guided Brachytherapy The Acuity BrachyTherapy Suite Integrating Imaging, Planning, and Treatment in a Single Room Each component draws on the

More information

RAPID DIAGNOSIS AND TREATMENT OF MDR-TB

RAPID DIAGNOSIS AND TREATMENT OF MDR-TB RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to

More information

7/30/2017. One World Medical Physics: Challenges and Opportunities in Cancer Care. Worldwide Demographic Shift

7/30/2017. One World Medical Physics: Challenges and Opportunities in Cancer Care. Worldwide Demographic Shift People 60 Years and Older ( in Millions) 7/30/2017 One World Medical Physics: Challenges and Opportunities in Cancer Care Jatinder R Palta PhD, FAAPM, FASTRO, FACR Virginia Commonwealth University, and

More information

Tobacco Insights May

Tobacco Insights May Tobacco Insights 2015 - May Product Code: TI0017MR Published Date: June 2015 Report Price: US$ 150 (Single Copy) Synopsis Tobacco Insights 2015 - May report is a qualitative report providing extensive

More information

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company

More information

Corporate Presentation. August 2016

Corporate Presentation. August 2016 v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,

More information

5 $3 billion per disease

5 $3 billion per disease $3 billion per disease Chapter at a glance Our aim is to set a market size large enough to attract serious commercial investment from several pharmaceutical companies that see technological opportunites,

More information

JEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016

JEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016 JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,

More information

Clinical Precision for Best Cancer Care. Dee Mathieson Senior Vice President Oncology Business Line Management

Clinical Precision for Best Cancer Care. Dee Mathieson Senior Vice President Oncology Business Line Management Clinical Precision for Best Cancer Care Dee Mathieson Senior Vice President Oncology Business Line Management Optimizing clinical results Key drivers in modern Radiation Therapy Clinical precision Continuous

More information

2015 Investor Conference

2015 Investor Conference 2015 Investor Conference ACCELERATING PROFITABLE GROWTH Jill Schaaf President, Renal Care Teeramanas Tanaekakarapong, ESRD Patient, Bangkok, Thailand Becoming The Global Leader In Renal Care Our Global

More information

Treatment Efficiency and Optimization of Patient Care with IBA ProteusOne

Treatment Efficiency and Optimization of Patient Care with IBA ProteusOne Treatment Efficiency and Optimization of Patient Care with IBA ProteusOne Terry Wu, Ph.D. Chief Physicist, Radiation Oncology Department Willis-Knighton Cancer Center/Proton Therapy Center Shreveport,

More information

The Global Alliance for Improved Nutrition

The Global Alliance for Improved Nutrition The Global Alliance for Improved Nutrition JCIE Seminar on Challenges in Global Health: New Opportunities for the Private Sector 27 July 2010, Tokyo 1 Outline Why Nutrition Matters About GAIN GAIN Nutrition

More information

Solvay expands its specialty polymers offerings with Ryton PPS acquisition

Solvay expands its specialty polymers offerings with Ryton PPS acquisition Solvay expands its specialty polymers offerings with Ryton PPS acquisition Sustained strategic portfolio realignment With Ryton PPS* acquisition, Solvay further strengthens unmatched leadership in Specialty

More information

Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc

Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc 1 Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc Safe Harbor Statement This presentation contains forward-looking statements within the meaning

More information

OPPORTUNITIES IN BRACHYTHERAPY

OPPORTUNITIES IN BRACHYTHERAPY OPPORTUNITIES IN BRACHYTHERAPY EDITION 2014 A report written by Paul-Emmanuel Goethals & Richard Zimmermann www.medraysintell.com Brachytherapy THE FIRST COMPREHENSIVE EVALUATION OF THE BRACHYTHERAPY INDUSTRY

More information

ON SHELF AVAILABILITY ALIGNMENT PROJECT 2011 ASIA PAC SURVEY RESULTS

ON SHELF AVAILABILITY ALIGNMENT PROJECT 2011 ASIA PAC SURVEY RESULTS ON SHELF AVAILABILITY ALIGNMENT PROJECT 2011 ASIA PAC SURVEY RESULTS Introduction The ECR Asia Pacific OSA working group conducted an online survey between July and September 2011 aimed at gaining insights

More information